Darunavir + ritonavir

Darunavir + ritonavir has been studied in 3 papers since 2016: 1 trial in people, 2 in cells. The newest paper, Dec 20, 2022: “Antiretroviral protease inhibitors induce features of cellular senescence that are reversible upon drug removal”.

Intervention

3 papers study it4 more mention it1 findingUpdated

PubChemPubChemChEBIChEBI

See all 7 papers on darunavir + ritonavir

At a glance

The findings reach cells, none yet in people. 1 lab in 1 country.

Cells: a single group. Worms or flies, mice and humans: nothing yet.
  • 1 lab in 1 country
  • Human trial1
  • Cells2

What did studies of darunavir + ritonavir find?

1

Studies of darunavir + ritonavir measured one outcome, cellular senescence.

Cellular senescence

upin human cells1

1 study
  1. Darunavir + ritonavir increases cellular senescence in endothelial cells from adult donors.

    “In endothelial cells from adult donors, we confirmed that ATV/r and DRV/r adversely affected all assessed endothelial functions and enhanced senescence”

    Cellsin endothelial cells from adult donorscoronary artery15 days

    Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence

    Antiviral therapy

More on Cellular senescence

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months